Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation

AIDS Research and Therapy

Volumn 7, Issue , 2010, Pages

  Heeregrave, Edwin J ^a   Geels, Mark J ^b   Baan, Elly ^a   van der Sluis, Renee M ^a   Paxton, William A ^a   Pollakis, Georgios ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Mark J Geels is currently employed at Nobilon International BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; LAMIVUDINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; EFFECTOR CELL; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT COURSE THERAPY; VIRUS ENVELOPE; VIRUS LATENCY; VIRUS LOAD; VIRUS STRAIN;

EID: 78649701534     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-7-42     Document Type: Article

References (43)

1. Mallon PW. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy. AIDS Rev 2007, 9:3-15.
2. Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009, 7:401-410. 10.1089/met.2008.0096, 19355810.
3. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. Aids 2009, 23:279-291. 10.1097/QAD.0b013e32831c54e5, 19114854.
4. Volmink J, Siegfried NL, Van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007, CD003510.
5. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK, Powell DA, Payne D, Haase AT, Garcia JV. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008, 5:e16. 10.1371/journal.pmed.0050016, 2194746, 18198941.
6. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180. 10.1056/NEJM199411033311801, 7935654.
7. The Centers for Disease Control and Prevention website. , http://www.cdc.gov/hiv/prep/resources/qa
8. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, Kuruppu J, Yazdani J, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol 2004, 78:1160-1168. 10.1128/JVI.78.3.1160-1168.2004, 321406, 14722271.
9. Heeregrave EJ, Geels MJ, Brenchley JM, Baan E, Ambrozak DR, van der Sluis RM, Bennemeer R, Douek DC, Goudsmit J, Pollakis G, Koup RA, Paxton WA. Lack of in vivo compartmentalization among HIV-1 infected naive and memory CD4+ T cell subsets. Virology 2009, 393:24-32. 10.1016/j.virol.2009.07.011, 2753733, 19698967.
10. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA 1997, 94:1925-1930. 10.1073/pnas.94.5.1925, 20019, 9050881.
11. Groot F, van Capel TM, Schuitemaker J, Berkhout B, de Jong EC. Differential susceptibility of naive, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology 2006, 3:52. 10.1186/1742-4690-3-52, 1562438, 16916447.
12. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005, 17:326-332. 10.1016/j.coi.2005.04.010, 15886125.
13. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Annu Rev Immunol 1992, 10:561-591. 10.1146/annurev.iy.10.040192.003021, 1590996.
14. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, Roederer M, Sherman MP, Chin PS, Goldsmith MA. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001, 15:671-682. 10.1016/S1074-7613(01)00217-5, 11672548.
15. Kinter A, Moorthy A, Jackson R, Fauci AS. Productive HIV infection of resting CD4+ T cells: role of lymphoid tissue microenvironment and effect of immunomodulating agents. AIDS Res Hum Retroviruses 2003, 19:847-856. 10.1089/088922203322493012, 14585216.
16. Delobel P, Sandres-Saune K, Cazabat M, L'Faqihi FE, Aquilina C, Obadia M, Pasquier C, Marchou B, Massip P, Izopet J. Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. Aids 2005, 19:1739-1750. 10.1097/01.aids.0000183125.93958.26, 16227781.
17. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, Adelsberger J, Ehler LA, Mizell SB, Hallahan CW, Fauci AS. Both memory and CD45RA+/CD62L+ naive CD4(+) T cells are infected in human immunodeficiency virus type 1-infected individuals. J Virol 1999, 73:6430-6435. 112723, 10400736.
18. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, O'Shea MA, Hallahan CW, Daucher M, Ward DJ, Moir S, Mullins JI, Kovacs C, Fauci AS. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005, 115:3250-3255. 10.1172/JCI26197, 1265878, 16276421.
19. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol 2009, 83:8470-8481. 10.1128/JVI.02568-08, 2738142, 19535437.
20. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009, 15:893-900. 10.1038/nm.1972, 2859814, 19543283.
21. Baldanti F, Paolucci S, Gulminetti R, Maserati R, Migliorino G, Pan A, Maggiolo F, Comolli G, Chiesa A, Gerna G. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. Antiviral Res 2001, 50:197-206. 10.1016/S0166-3542(01)00142-5, 11397507.
22. The Los Alamos database website. , http://www.hiv.lanl.gov
23. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990, 28:495-503. 269651, 1691208.
24. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599. 10.1093/molbev/msm092, 17488738.
25. Nabatov AA, Pollakis G, Linnemann T, Kliphuis A, Chalaby MI, Paxton WA. Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 2004, 78:524-530. 10.1128/JVI.78.1.524-530.2004, 303404, 14671134.
26. Schols D, Este JA, Cabrera C, De Clercq E. T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use. J Virol 1998, 72:4032-4037. 109631, 9557691.
27. Ince WL, Harrington PR, Schnell GL, Patel-Chhabra M, Burch CL, Menezes P, Price RW, Eron JJ, Swanstrom RI. Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization. J Virol 2009, 83:4068-4080. 10.1128/JVI.02486-08, 2668457, 19211740.
28. Gondois-Rey F, Biancotto A, Fernandez MA, Bettendroffer L, Blazkova J, Trejbalova K, Pion M, Hirsch I. R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors. J Virol 2006, 80:854-865. 10.1128/JVI.80.2.854-865.2006, 1346836, 16378987.
29. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191. 10.1038/387188a0, 9144290.
30. Valentin A, Morrow M, Poirier RH, Aleman K, Little R, Yarchoan R, Pavlakis GN. Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4(+) primary cells. AIDS Res Hum Retroviruses 2010, 26:79-88. 10.1089/aid.2009.0044, 20059395.
31. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992, 70:539-544. 10.1007/BF00184787, 1392422.
32. Jordan MR, Kearney M, Palmer S, Shao W, Maldarelli F, Coakley EP, Chappey C, Wanke C, Coffin JM. Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations. J Virol Methods 2010, 168:114-120. 10.1016/j.jviromet.2010.04.030, 20451557.
33. Chun TW, Davey RT, Ostrowski M, Shawn JJ, Engel D, Mullins JI, Fauci AS. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000, 6:757-761. 10.1038/77481, 10888923.
34. Sahu GK, Paar D, Frost SD, Smith MM, Weaver S, Cloyd MW. Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol 2009, 81:9-15. 10.1002/jmv.21366, 2912142, 19031450.
35. Geeraert L, Kraus G, Pomerantz RJ. Hide-and-seek: the challenge of viral persistence in HIV-1 infection. Annu Rev Med 2008, 59:487-501. 10.1146/annurev.med.59.062806.123001, 17845138.
36. Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, Gaddam A, Bosche M, Metcalf JA, Davey RT, Lane HC. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy. J Infect Dis 2001, 183:36-50. 10.1086/317641, 11106537.
37. Joos B, Fischer M, Kuster H, Pillai SK, Wong JK, Boni J, Hirschel B, Weber R, Trkola A, Gunthard HF. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA 2008, 105:16725-16730. 10.1073/pnas.0804192105, 2575487, 18936487.
38. van Opijnen T, Boerlijst MC, Berkhout B. Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol 2006, 80:6678-6685. 10.1128/JVI.02547-05, 1488947, 16775355.
39. van der Kuyl AC, Cornelissen M. Identifying HIV-1 dual infections. Retrovirology 2007, 4:67. 10.1186/1742-4690-4-67, 2045676, 17892568.
40. Schutten M, van der Ende ME, Osterhaus AD. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N Engl J Med 2000, 342:1758-1760. 10.1056/NEJM200006083422317, 10858105.
41. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265. 10.1038/nm1197-1259, 9359702.
42. De Jong JJ, de Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol 1992, 66:6777-6780. 240176, 1404617.
43. Nicholson JK, Browning SW, Hengel RL, Lew E, Gallagher LE, Rimland D, McDougal JS. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001, 27:105-115.